新辅助药relugolix对患者报告的多维疲劳的影响
Jessica Y Hsueh1, Lindsey Gallagher1, Min Ji Koh1
1Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.
Frontiers in oncology
|August 27, 2024
概括
新辅助药relugolix在接受SBRT的前列腺癌患者中显著增加了疲劳,影响了日常生活的感知. 临床医生应该与患者讨论这些对生活质量的影响.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 与放射治疗相结合的雄激素剥夺疗法 (ADT) 改善了癌症控制.
- 雷卢戈力克斯是一种口服的GnRH受体对抗剂,可诱导快速的抑制.
- 在癌症患者中,ADT可能会加剧疲劳.
研究的目的:
- 评估前列腺癌患者在立体辐射疗法 (SBRT) 之前的neoadjuvant relugolix诱导的疲劳.
- 通过使用FACIT-F问卷来评估relugolix对患者报告的疲劳的影响.
主要方法:
- 89名前列腺癌患者在SBRT之前接受了新辅助药relugolix.
- 慢性疾病治疗-疲劳 (FACIT-F) 的13项功能评估在基线和SBRT之前进行.
- 疲劳得分的统计和临床意义被分析使用对联t测试和MID.
主要成果:
- 87名患者完成了FACIT-F;平均整体得分从45.6降至41.0 (p < 0.01,MID = 3.55),表明疲劳增加.
- 在13个疲劳项目中,有11个表现出了统计学上显著的恶化.
- 在5个"经验"疲劳项中的3个和8个"冲击"疲劳项中的2个具有临床意义.
结论:
- 新辅助药relugolix显著增加前列腺癌患者的疲劳.
- 虽然通常不会影响日常活动的表现,但患者报告说,由于疲劳而感到丧.
- 临床医生必须向患者提供关于relugolix引起的疲劳及其对生活质量的影响的建议.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
01:21Drugs for Treatment of Constipation-Predominant IBS
146
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
146